Plain-English fact sheet
Survodutide
Also known as BI 456906
Survodutide combines GLP-1 and glucagon receptor activity. Human trials show weight and liver-fat effects, but it remains investigational and is not an approved treatment.
Quick answer
Survodutide is not FDA approved. Phase 2 and Phase 3 trials have reported weight loss, reduced liver fat, and MASH-resolution signals, while fibrosis outcomes, longer-term benefits, safety, and regulatory decisions remain under study.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Survodutide?
Survodutide is a manufactured peptide that activates both the glucagon and GLP-1 receptors.
The dual design aims to combine appetite and glucose effects with glucagon-related energy and liver biology, but mechanistic breadth can also create tradeoffs.
Why are people interested in it?
It is among the most advanced dual glucagon/GLP-1 candidates for obesity and metabolic liver disease.
Recent Phase 3 liver-fat results strengthen the human evidence without turning an investigational program into an approved medicine.
Current regulatory status
Survodutide remains investigational in the United States and is being evaluated in Phase 3 obesity and metabolic liver-disease programs.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Chronic weight management
- MASH and MASLD
- Obesity with or without type 2 diabetes
Evidence snapshot
Randomized Phase 2 studies and a Phase 3 MASLD study report meaningful weight and liver-fat effects. Those endpoints do not yet establish broad liver-outcome, cardiovascular, or long-term clinical benefit.
Potential benefits being researched
- A Phase 2 obesity trial reported substantial average weight reduction compared with placebo.
- MASH and MASLD trials reported favorable resolution or liver-fat endpoints, while fibrosis and long-term clinical outcomes require further evidence.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- Gastrointestinal adverse effects were the most frequent treatment-emergent problems in trials.
- Discontinuation and incomplete exposure complicate estimates of real-world benefit.
- Long-term glucagon-receptor effects and uncommon harms remain under study.
What we still do not know
- Whether liver-fat and MASH-resolution changes translate into fewer liver complications
- Long-term cardiovascular, gallbladder, pancreatic, and metabolic outcomes
- Durability of weight and liver effects
- Whether the benefit-risk profile will support FDA approval
Plain-English takeaway
Survodutide is a credible late-stage metabolic and liver candidate. Its trial results are promising, but approval and patient-centered long-term outcomes remain open questions.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1Randomized Phase 2 obesity trial
Controlled human study of body-weight efficacy, tolerability, and adverse events.
- 2Randomized Phase 2 MASH trial
Biopsy-based MASH and fibrosis study with condition-specific endpoints.
- 3SYNCHRONIZE-MASLD Phase 3 trial
Phase 3 liver-fat and body-weight trial with limited duration and geography.
- 4ClinicalTrials.gov: SYNCHRONIZE-1
Official Phase 3 obesity-study record and endpoint definitions.